3,3-Difluoro-5-(hydroxymethyl)-1-methylpyrrolidin-2-one

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡咯烷类
• 英文名称: 3,3-Difluoro-5-(hydroxymethyl)-1-methylpyrrolidin-2-one
• 英文别名: 3,3-difluoro-5-(hydroxymethyl)-1-methylpyrrolidin-2-one
• 化学式: C₆H₉F₂NO₂
• 分子量: 165.14
• InChiKey: MCCZJRIYTQJRCN-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -0.1
• 重原子数：
  11
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.83
• 拓扑面积：
  40.5
• 氢给体数：
  1
• 氢受体数：
  4

文献信息

• [EN] DIFLUOROLACTAM COMPOSITIONS FOR EP4-MEDIATED OSTEO RELATED DISEASES AND CONDITIONS<br/>[FR] COMPOSITIONS DE DIFLUOROLACTAME DESTINÉES À DES MALADIES ET DES AFFECTIONS OSSEUSES MÉDIÉES PAR EP4
  申请人：CAYMAN CHEMICAL CO INC

  公开号：WO2014015246A1

  公开（公告）日：2014-01-23

  Disclosed herein are compositions and methods of treating osteroporosis, bone fracture, bone loss, and increasing bone density by administration of compounds of formula (I) or compositions comprising a compound of formula (I) and a pharmaceutically acceptable carrier, wherein L1, L2, L4, R1, R4, R5, R6, and s are as defined in the specification.

  披露的是通过给予公式(I)化合物的组合物和方法来治疗骨质疏松症、骨折、骨丢失以及增加骨密度，其中组合物包含公式(I)的化合物和药用可接受的载体，其中L1、L2、L4、R1、R4、R5、R6和s按说明书定义。
• DIFLUOROLACTAM COMPOSITIONS FOR EP4-MEDIATED OSTEO RELATED DISEASES AND CONDITIONS
  申请人：Cayman Chemical Company, Incorporated

  公开号：EP3175852A1

  公开（公告）日：2017-06-07

  Disclosed herein are compositions and methods of treating osteroporosis, bone fracture, bone loss, and increasing bone density by administration of compounds of formula (I) or compositions comprising a compound of formula (I) and a pharmaceutically acceptable carrier, wherein L1, L2, L4, R1, R4, R5, R6, and s are as defined in the specification.

  本文公开了通过施用式 (I) 化合物治疗牡蛎性骨质疏松症、骨折、骨质流失和增加骨密度的组合物和方法。 或包含式（I）化合物和药学上可接受的载体的组合物，其中 L1、L2、L4、R1、R4、R5、R6 和 s 如说明书中所定义。
• Methods, systems, and compositions for promoting bone growth
  申请人：Cayman Chemical Company, Inc.

  公开号：US10729810B2

  公开（公告）日：2020-08-04

  The present invention relates to novel bone compositions for locally delivering a therapeutic agent to the site of a bone defect. Therapeutic agents may promote repair of the bone defect and/or treat conditions or disorders such as pain, inflammation, cancer, and infection. The compositions include calcium phosphate cements and a demineralized bone matrix or a collagen sponge. The compositions are useful for implantation in a patient at the site of a bone defect.

  本发明涉及用于向骨缺损部位局部输送治疗剂的新型骨组合物。治疗剂可促进骨缺损的修复和/或治疗疼痛、炎症、癌症和感染等疾病。组合物包括磷酸钙骨水泥和脱矿骨基质或胶原海绵。这些组合物可用于植入患者骨缺损部位。
• DIFLUOROLACTAM COMPOSITIONS FOR EP4-MEDIATED OSTEO RELATED DISEASES AND CONDTIONS
  申请人：Cayman Chemical Company, Inc.

  公开号：US20170260173A1

  公开（公告）日：2017-09-14

  Disclosed herein are compositions and methods of treating osteroporosis, bone fracture, bone loss, and increasing bone density by administration of compounds of formula (I) or compositions comprising a compound of formula (I) and a pharmaceutically acceptable carrier, wherein L 1 , L 2 , L 4 , R 1 , R 4 , R 5 , R 6 , and s are as defined in the specification.
• US9701630B2
  申请人：——

  公开号：US9701630B2

  公开（公告）日：2017-07-11